Antiphospholipid antibodies associated with alcoholic liver disease specifically recognise oxidised phospholipids.
BACKGROUND
Circulating antiphospholipid antibodies (aPL) are often detected in patients with alcoholic liver disease (ALD) but little is known about the causes of their formation.


OBJECTIVE
We have evaluated whether ethanol mediated oxidative injury might promote the development of aPL in ALD.


METHODS
IgG against beta(2) glycoprotein 1 (beta(2)-GP1), cardiolipin, and human serum albumin (HSA) complexed with either oxidised arachidonic acid (HSA-APP) or malondialdehyde (HSA-MDA) were assayed by ELISA in heavy drinkers with or without ALD and in healthy subjects.


RESULTS
Circulating IgG recognising cardiolipin were significantly higher in ALD patients than in controls. However, anticardiolipin reactivity of ALD sera was only evident using, as the antigen, oxidised cardiolipin but not oxidation protected cardiolipin. In ALD patients, individual values of IgG antioxidised cardiolipin were associated with the titres of antibodies against HSA-MDA and HSA-APP (r=0.68 and 0.72, respectively; p<0.0001) used as markers of oxidative stress. ALD patients also displayed increased levels of antibodies against phospholipid binding protein beta(2)-GP1, and individual reactivity towards oxidised cardiolipin and beta(2)-GP1 were highly correlated (r=0.85; p<0.0001). IgG binding to oxidised cardiolipin, HSA-MDA, and HSA-APP was also significantly higher in beta(2)-GP1 positive than in beta(2)-GP1 negative sera. However, preadsorption of beta(2)-GP1 positive sera on beta(2)-GP1 coated ELISA plates reduced reactivity to oxidised cardiolipin by 80%, without affecting that to HSA-APP or HSA-MDA.


CONCLUSIONS
Ethanol induced oxidative injury is associated with the development of antibodies targeting complexes between oxidised cardiolipin and beta(2)-GP1. These antibodies might account for high aPL titres observed in patients with severe ALD.
Rolla
R
R
Department of Medical Sciences and Medical Clinic, University Amedeo Avodagro of East Piedmont, Via Solaroli 17, 28100, Novara, Italy.
Vay
D
D
Mottaran
E
E
Parodi
M
M
Vidali
M
M
Sartori
M
M
Rigamonti
C
C
Bellomo
G
G
Albano
E
E
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D017153:Antibodies, Anticardiolipin / Q000097:blood; D017152:Antibodies, Antiphospholipid / Q000032:analysis*; D016718:Arachidonic Acid / Q000378:metabolism; D016022:Case-Control Studies; D005260:Female; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D015227:Lipid Peroxidation; D008099:Liver / Q000378:metabolism; D008108:Liver Diseases, Alcoholic / Q000276:immunology* / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D008875:Middle Aged; D010743:Phospholipids / Q000276:immunology*; D053482:beta 2-Glycoprotein I
D017153:Antibodies, Anticardiolipin; D017152:Antibodies, Antiphospholipid; D006023:Glycoproteins; D007074:Immunoglobulin G; D010743:Phospholipids; D053482:beta 2-Glycoprotein I; D016718:Arachidonic Acid; D008315:Malondialdehyde